Compare CORT & TFPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | TFPM |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 6.5B |
| IPO Year | 2001 | 2022 |
| Metric | CORT | TFPM |
|---|---|---|
| Price | $120.92 | $33.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $96.50 | $40.00 |
| AVG Volume (30 Days) | ★ 1.1M | 474.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | $29.19 |
| Revenue Next Year | $26.98 | N/A |
| P/E Ratio | $1,345.00 | ★ $35.57 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $26.00 |
| 52 Week High | $122.21 | $41.70 |
| Indicator | CORT | TFPM |
|---|---|---|
| Relative Strength Index (RSI) | 70.05 | 66.33 |
| Support Level | $77.73 | $32.31 |
| Resistance Level | $122.21 | $34.33 |
| Average True Range (ATR) | 3.53 | 0.90 |
| MACD | 0.20 | 0.22 |
| Stochastic Oscillator | 84.57 | 87.58 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.